SCYNEXIS announces amendment to exclusive license agreement with GSK including wind down of MARIO study and receipt of 224 million in payments

Reuters10-15

SCYNEXIS announces amendment to exclusive license agreement with GSK including wind down of MARIO study and receipt of 224 million in payments

SCYNEXIS Inc. announced that it has entered into a binding memorandum of understanding with GlaxoSmithKline Intellectual Property (No. 3) Limited $(GSK)$ to amend their exclusive license agreement related to ibrexafungerp, including the approved product BREXAFEMME®. Under the amended terms, SCYNEXIS has agreed to wind down and terminate the Phase 3 MARIO study of ibrexafungerp for the treatment of invasive candidiasis. As part of the agreement, SCYNEXIS will receive a $22 million payment from GSK, as well as an additional $2.3 million payment related to the wind-down and termination activities. SCYNEXIS will not receive further milestone payments from GSK specifically associated with the MARIO study.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SCYNEXIS Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178253-25-000006), on October 15, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2575781713?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-15 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575781713","market":"us","top_or_hot":-1,"title":"SCYNEXIS announces amendment to exclusive license agreement with GSK including wind down of MARIO study and receipt of 224 million in payments","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      SCYNEXIS announces amendment to exclusive license agreement with GSK including wind down of MARIO study and receipt of 224 million in payments\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SCYX\">SCYNEXIS Inc</a>. announced that it has entered into a binding memorandum of understanding with GlaxoSmithKline Intellectual Property (No. 3) Limited <a href=\"https://laohu8.com/S/GSK\">$(GSK)$</a> to amend their exclusive license agreement related to ibrexafungerp, including the approved product BREXAFEMME®. Under the amended terms, SCYNEXIS has agreed to wind down and terminate the Phase 3 MARIO study of ibrexafungerp for the treatment of invasive candidiasis. As part of the agreement, SCYNEXIS will receive a $22 million payment from GSK, as well as an additional $2.3 million payment related to the wind-down and termination activities. SCYNEXIS will not receive further milestone payments from GSK specifically associated with the MARIO study.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SCYNEXIS Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178253-25-000006), on October 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SCYNEXIS announces amendment to exclusive license agreement with GSK including wind down of MARIO study and receipt of 224 million in payments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSCYNEXIS announces amendment to exclusive license agreement with GSK including wind down of MARIO study and receipt of 224 million in payments\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-15 20:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      SCYNEXIS announces amendment to exclusive license agreement with GSK including wind down of MARIO study and receipt of 224 million in payments\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SCYX\">SCYNEXIS Inc</a>. announced that it has entered into a binding memorandum of understanding with GlaxoSmithKline Intellectual Property (No. 3) Limited <a href=\"https://laohu8.com/S/GSK\">$(GSK)$</a> to amend their exclusive license agreement related to ibrexafungerp, including the approved product BREXAFEMME®. Under the amended terms, SCYNEXIS has agreed to wind down and terminate the Phase 3 MARIO study of ibrexafungerp for the treatment of invasive candidiasis. As part of the agreement, SCYNEXIS will receive a $22 million payment from GSK, as well as an additional $2.3 million payment related to the wind-down and termination activities. SCYNEXIS will not receive further milestone payments from GSK specifically associated with the MARIO study.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SCYNEXIS Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178253-25-000006), on October 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0306806265.USD","symbol_name":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251015:nNDL2f9Bbr:1","article_id":"2575781713","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575781713","pubTimestamp":1760529676,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"SCYNEXIS announces amendment to exclusive license agreement with GSK including wind down of MARIO study and receipt of 224 million in payments. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SCYNEXIS Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 15, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","LU1645745479.HKD":"ALLIANZ EUROPE INCOME AND GROWTH \"AM\" (HKDHDG) INC","GSK.UK":"葛兰素史克","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","LU0971552673.USD":"Allianz European Equity Dividend Cl AM DIS H2-USD","LU1035777561.USD":"AB SICAV I - EUROPEAN EQUITY PORTFOLIO \"A\" (USDHDG) ACC","LU1400636491.USD":"Allianz Europe Income and Growth Cl AMg DIS H2-USD","SCYX":"SCYNEXIS Inc","LU1098665638.USD":"FRANKLIN MUTUAL EUROPEAN \"A\" (USDHDG) H1 ACC","IE00BQJZX424.USD":"FRANKLIN MV EUROPEAN EQUITY GROWTH AND INCOME \"A\" (USDHDG) INC","LU1400636657.SGD":"Allianz Europe Income and Growth Cl AMg DIS H2-SGD","LU1481600234.SGD":"THREADNEEDLE (LUX) UK EQUITY INCOME \"ASC\" (SGDHDG) INC","LU1015430645.USD":"SCHRODER ISF UK EQUITY \"A\" (USDHDG) ACC","LU1228905037.USD":"NINETY ONE GSF GLOBAL QUALITY DIVIDEND GROWTH \"A\" (USD) ACC","IE00BWDBJ516.SGD":"Legg Mason QS - MV European Equity Growth and Income A Mdis SGD-H Plus","LU1046248800.SGD":"Allianz European Equity Dividend Cl AM DIS H2-SGD","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","BK5011":"制药","LU1487256676.USD":"THREADNEEDLE (LUX) UK EQUITY INCOME \"ZUH\" (USDHDG) ACC","LU1228905540.USD":"NINETY ONE GSF GLOBAL QUALITY DIVIDEND GROWTH \"A\" (USD) INC 2","LU1400636574.HKD":"ALLIANZ EUROPE INCOME AND GROWTH \"AMG\" (HKDHDG) INC","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU1064927863.SGD":"JPMorgan Funds - Europe Dynamic A (acc) SGD-H","LU0109981661.USD":"FRANKLIN MUTUAL EUROPEAN \"A\" (USD) ACC","LU1670756490.USD":"ALLIANZ EUROPE INCOME AND GROWTH \"AT\" (USDHDG) ACC","LU0058720904.USD":"联博国际健康护理基金A","LU0575583348.USD":"SCHRODER ISF UK EQUITY \"A\" (USD) INC AV","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU1302929846.USD":"ALLIANZ EUROPEAN EQUITY DIVIDEND \"AMG\" (USDHDG) INC","LU1202635105.USD":"ALLIANZ EUROPE INCOME AND GROWTH \"AM\" (USDHDG) INC","LU0161305163.EUR":"SCHRODER ISF EUROPEAN VALUE \"A\" (EUR) ACC","LU1309081286.SGD":"SCHRODER ISF EUROPEAN VALUE \"A\" (SGDHDG) ACC","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","IE0034235071.USD":"PINEBRIDGE EUROPE RESEARCH ENHANCED EQUITY \"A\" (USD) ACC","BK4007":"制药","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","LU0971552830.HKD":"ALLIANZ EUROPEAN EQUITY DIVIDEND \"AM\" (HKDHDG) INC","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU0545562505.USD":"NINETY ONE GSF GLOBAL QUALITY DIVIDEND GROWTH \"A\" (USD) INC","LU1481599808.USD":"THREADNEEDLE (LUX) UK EQUITY INCOME \"AUC\" (USDHDG) INC"},"translate_title":"SCYNEXIS宣布修订与GSK的独家许可协议，包括结束MARIO研究并收到2.24亿美元的付款","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GSK.UK":0.9,"SCYX":0.9},"content_text":"SCYNEXIS announces amendment to exclusive license agreement with GSK including wind down of MARIO study and receipt of 224 million in payments\n    \n\nSCYNEXIS Inc. announced that it has entered into a binding memorandum of understanding with GlaxoSmithKline Intellectual Property (No. 3) Limited $(GSK)$ to amend their exclusive license agreement related to ibrexafungerp, including the approved product BREXAFEMME®. Under the amended terms, SCYNEXIS has agreed to wind down and terminate the Phase 3 MARIO study of ibrexafungerp for the treatment of invasive candidiasis. As part of the agreement, SCYNEXIS will receive a $22 million payment from GSK, as well as an additional $2.3 million payment related to the wind-down and termination activities. SCYNEXIS will not receive further milestone payments from GSK specifically associated with the MARIO study.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SCYNEXIS Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178253-25-000006), on October 15, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2575781713","isCrawlerRequest":true}